400%-Chance - 500 Beiträge pro Seite

[Meister+M+]

The use of genomic and proteomic approaches are essential to the development of future pharmaceutical products. Today`s drug target discoveries will lead to new therapies that treat the underlying cause of the disease, not just its symptoms. Strategic alliances enable Myriad to significantly accelerate its research activities leading to the development of these new therapies, while building core capabilities and technologies. Through partnerships with major companies in the pharmaceutical industry, Myriad has sought not only to fund its extensive research and product development efforts, but to facilitate development of new therapeutics based on its gene and disease pathway discoveries in a number of important disease areas. To date, the Company has forged agreements with the following companies.


Bayer Corporation -- a major international chemical and health-care company, Bayer is funding Myriad initiatives to discover and sequence certain genes relating to depression, dementia, obesity, osteoporosis and asthma

Eli Lilly and Company -- a global, research based pharmaceutical corporation, Eli Lilly funded research that led to Myriad`s discovery and sequencing of the BRCA1 breast and ovarian cancer susceptibility gene.

Monsanto -- a life sciences company, is committed to finding solutions to the growing global needs for food and health by sharing common forms of science and technology among agriculture, nutrition and health. Monsanto is using Myriad`s ProNet technology explore disease pathways and discover new therapeutic targets.

Novartis Agricultural Discovery Institute, Inc. (NADII) -- one of the world`s largest single research endeavors dedicated to agricultural genomics research and development. It applies genomics technologies to the development of improved plant traits, new methods for crop protection, and new animal health products, which enhance human life in an environmentally sustainable manner. NADII is using Myriad`s high-throughput sequencing capabilities to discover the structure of important food crop plants such as rice, corn, wheat, rye and barley.

Novartis Corporation -- a global leader in the life sciences, committed to health and well-being through innovative products and services. Novartis is collaborating with Myriad Genetics in the effort to discover and sequence cardiovascular disease genes.

Roche -- one of the world¹s leading research-based healthcare groups active in the discovery, development and manufacture of pharmaceuticals and diagnostic systems. Myriad is identifying the components of a major cardiovascular disease pathway to isolate the potential drug targets for Roche.

Schering AG --is an International research-based pharmaceutical company with headquarters in Germany, whose contribution to medical research is acknowledged the world over. Schering uses ProNet technology to discover drugs with improved efficacy and specificity for improved health care.

Schering-Plough --a research-based company engaged in the discovery, development, manufacturing and marketing of pharmaceutical and health-care products worldwide is collaborating with Myriad to discover genes and develop therapies for prostate cancer and other cancers.

Chart ansehen!!!

[lexcougar]

recht interessant. Bitte die Quellenangabe. Gibt`s denn auch
Info über Umsatz- und Gewinnentwicklung und Erwartungen dazu?

Gruß Lexcougar